Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC
出版年份 2018 全文链接
标题
Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC
作者
关键词
-
出版物
Cancer Medicine
Volume 7, Issue 11, Pages 5505-5513
出版商
Wiley
发表日期
2018-10-12
DOI
10.1002/cam4.1825
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer
- (2018) Harper G. Hubbeling et al. Journal of Thoracic Oncology
- PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes
- (2018) Shisuo Du et al. Journal of Thoracic Oncology
- Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
- (2018) Aaron Lisberg et al. Cancer Immunology Research
- Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
- (2018) William L. Hwang et al. JAMA Oncology
- Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues
- (2017) Carey J. Myers et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy
- (2017) Andrew Bang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy
- (2017) Amélie Aboudaram et al. MELANOMA RESEARCH
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
- (2016) K. A. Ahmed et al. ANNALS OF ONCOLOGY
- Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?
- (2016) Richard C Walshaw et al. BRITISH JOURNAL OF RADIOLOGY
- Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab
- (2016) Rosie Qin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
- (2016) Noboru Yamamoto et al. INVESTIGATIONAL NEW DRUGS
- Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
- (2016) Jeffrey S. Weber et al. ONCOLOGIST
- Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
- (2016) E. Liniker et al. OncoImmunology
- Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy
- (2015) K. A. Ahmed et al. ANNALS OF ONCOLOGY
- Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment
- (2015) Ana P. Kiess et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
- (2015) Andrew B Sharabi et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
- (2013) Patrick Royston et al. BMC Medical Research Methodology
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of T lymphocytes in tumor response to radiotherapy
- (2012) Sandra Demaria et al. Frontiers in Oncology
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
- (2011) Patrick Royston et al. STATISTICS IN MEDICINE
- Up-regulation of the Pro-inflammatory Chemokine CXCL16 is a Common Response of Tumor Cells to Ionizing Radiation
- (2010) Satoko Matsumura et al. RADIATION RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started